An ascending single-dose safety and tolerance study of an oral formulation of rabeprazole (E3810)

Alimentary Pharmacology and Therapeutics

Volumn 12, Issue 7, 1998, Pages 667-672

  Lew, E A ^a   Barbuti, R C ^a   Kovacs, T O G ^a   Sytnic, B ^a   Humphries, T J ^b   Walsh, J H ^a,c  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b EISAI CO LTD   (Japan)

^c VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PLACEBO; PROTON PUMP INHIBITOR; RABEPRAZOLE;

ADULT; ARTICLE; CLINICAL TRIAL; CONTROLLED STUDY; DOSE RESPONSE; DRUG SAFETY; GASTRIN BLOOD LEVEL; HUMAN; HUMAN EXPERIMENT; MALE; NORMAL HUMAN; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; STOMACH ACID SECRETION;

2-PYRIDINYLMETHYLSULFINYLBENZIMIDAZOLES; ADMINISTRATION, ORAL; ADULT; ANTI-ULCER AGENTS; AREA UNDER CURVE; BENZIMIDAZOLES; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; GASTRIC ACID; GASTRINS; HALF-LIFE; HUMANS; HYDROGEN-ION CONCENTRATION; MALE; OMEPRAZOLE; PROTON PUMPS;

EID: 0031847847     PISSN: 02692813     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2036.1998.00356.x     Document Type: Article

References (22)

1. Park JB, Imamura L, Kobashi K. Kinetics studies of Helicobacter pylori ureuse inhibition by a novel proton pump inhibitor, rabeprazole. Biol Pharm Bull 1996; 19: 182-7.
2. Fujisaki H, Shibata H, Oketani K. et al. Inhibitions of acid secretion by E3810 and omeprazole, and their reversal by glutathione. Biochem Pharm 1991; 42: 321-8.
3. + ATPase by E3810. Chem Pharm Bull 1996; 3: 552-8.
4. Fujisaki H, Shibata H, Oketani K. et al. Effects of the proton inhibitor. E3810. on gastric acid secretion and gastric duodenal ulcers or erosions in rats. Drug Invest 1991; 3: 328-32.
5. Inoue M, Komatsu H, Kawamoto Y. et al. A study of the effects of the proton pump inhibitor E3810 (rabeprazole sodium) on gastric pH. Jpn Arch Int Med 1994; 41: 99-106.
6. Motomura A, Arita M, Sakurai T. et al. An open randomized dose-response trial of two doses of E3810 (rabeprazole sodium) in patients with duodenal or gastric ulcers. with 24 hour pH monitoring in gastric ulcer patients. Modern Physician 1994; 14: 23-37.
7. Inoue M, Ikishoji M, Toa C. et al. A study of the effects of the proton pump inhibitor E3810 (rabeprazole sodium) on gastric juice secretion. Jpn Arch Int Med 1994; 41: 143-50.
8. Sakegushi M, Ashida K, Ohsiba S. A Comparison of the Effects of 7 Days Dosing of the Proton Pump Inhibitor E 3810 or Omeprazole on Intragastric pH. Serum, and Urinary Levels in Healthy Volunteer. Tokyo. Japan: Eisai Co., Ltd. 1996.
9. Hongo M, Ohara S, Asaki S. et al. A comparison of Two Doses of the Proton Pump Inhibitor E3810 (Rabeprazole Sodium) Versus Famotidine and Pirenzepine Using a 24 Hour Monitoring of Gastric pH in Healthy Volunteers. Tokyo. Japan: Eisai Co., Ltd. 1996.
10. Freston JW. Long term acid control and proton pump inhibitors: interactions and safety issues in perspective. Am J Gastroenterol 1997; 92 (Suppl. 4): 51-5.
11. Bardhan KD. Is there any acid peptic disease that is refractory to proton pump inhibitor? Alimen Pharmacol Ther 1993; 7 (Suppl. 1): 13-24.
12. Huber R, Kohl B, Sachs G, Senn-Bilfinger J, Simon WA. Review article: the continuing development of proton inhibitors with particular reference to pantoprazole. Aliment Pharmacol Ther 1995; 9: 363-78.
13. Lind T, Cedeberg C, Ekenved G, Haglund U, Olbe L. Effects of omeprazole - a gastric proton pump inhibitor on Pentagastrin stimulated acid secretion in man. Gut 1983; 24: 270-2.
14. Sakagushi K, Ashida S, Ohshiba S, Fukai M. Inhibitory effect of the novel proton pump inhibitor E3810 on gastric acid secretion as clinically determined by intragastric pH monitoring. Abstract at 10th world congress of Gastroenterology. Los Angeles. CA. Am J Gastroenterol 1994; 89 (Suppl. 8): 684.
15. Shamburek RD, Schubert ML. Control of acid secretion. Gastroenterol Pharm 1993; 21: 527-50.
16. Cedeberg C, Andersson T, Skanberg I. Omeprazole: the pharmacokinetics and metabolism in man. Scan J Gastro Suppl 1989; 166: 33-44.
17. Andersson T, Cedeberg C, Heggerlund A, Lundborg P. The pharmacokinetics of single and repeated once daily doses of 10, 20, and 40 mg omeprazole as enteric coated granules. Drug Invest 1991; 3: 45-52.
18. McTavish D, Buckley MT, Heel RC. Omeprazole. Drugs 1991; 42: 138-70.
19. Barradell LB, Faulds D, McTavish D. Lansoprazole. Drugs 1992; 44: 225-50.
20. Kromer W. Similarities and differences in the properties of substituted benzimidazoles: a comparison between pantoprazole and related compounds. Digestion 1995; 56: 443 54.
21. Andersson T, Cedeberg C. Regardh CG. Skanberg I. Pharmacokinetics of various single intravenous and oral doses of omeprazole. Eur J Clin Pharm 1990; 39: 195-7.
22. Pue MA, Laroche J, Meincke I, DeMey C. Pharmacokinetics of pantoprazole following single intravenous and oral administration to healthy male subjects. Eur J Pharm 1993: 44: 575-8.